Arkolith/Insider Trading/SNDX/Form 4

Goldan Keith A.

Chief Financial OfficerSyndax Pharmaceuticals Inc (SNDX) · full profile →Form 4 · filed Feb 7, 2025
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Feb 5, 2025Grant(A)19K—$071K
Feb 5, 2025Grant(A)23K—$095K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Feb 5, 2025Grant(A)111K$14.65$1.6M111K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-25-016389) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML